Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation
NCT: NCT07649603 · NOT_YET_RECRUITING
Brief Summary
Pulmonary vein isolation (PVI) via catheter ablation has been successfully employed for years to treat symptomatic atrial fibrillation (AF). Moreover, PVI has not been used as a prophylactic intervention even in groups known to be high-risk for the future development of AF. Preliminary studies, including our pilot PREVENT AF I randomized trial, suggested that prophylactic PVI may be effective at reducing new onset AF and overall AF burden in atrial flutter (AFL) patients. This is a multicenter single-blind randomized controlled trial, "Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation" (PREVENT AF II) to determine if PVI in conjunction with AFL ablation for patients with typical AFL results in a significant reduction in cardiac events and healthcare utilization.
Frequently Asked Questions
What is Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation?
Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation is a clinical trial registered under NCT07649603. Current status: NOT_YET_RECRUITING.
What is the status of NCT07649603?
The current status of NCT07649603 (Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation) is: NOT_YET_RECRUITING.
When did Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation start?
Prophylactic Pulmonary Vein Isolation During Atrial Flutter Ablation started on 2027-06.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.